With just over 100 days as CEO now under her belt, Catherine Owen Adams is looking to cruise rare disease-focused Acadia ...
The roller-coaster ride for Novartis—as it uses every bit of its legal muscle to extend Entresto's market exclusivity—took ...
Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...
Fierce Pharma Asia—AbbVie's $1B pact with Simcere; Takeda's launch map; Samsung Bio's growth plans
As the J.P. Morgan Healthcare Conference started in San Francisco on Monday, AbbVie linked up with Simcere with a $1 billion ...
About two and a half years after originating the role of chief commercial officer at Arvinas, John Northcott is leaving his post at the biotech. | About two and a half years after originating the role ...
In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...
The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...
GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...
Following the strange year for the biopharma industry that was 2024, insiders and analysts alike are waiting expectantly to ...
The FDA established its accelerated approval program in 1992 to allow drugs to reach the market quickly for life-threatening ...
Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and ...
Kite Pharma is flying high with the addition of a new member to its senior leadership team. | Kite Pharma is flying high with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback